Aceon Gets Coronary Artery Disease Approval Ahead Of Schedule
This article was originally published in The Pink Sheet Daily
Aceon adds indication for reduction of risk of cardiovascular mortality and non-fatal myocardial infarction in patients with stable coronary artery disease ahead of Sept. 10 user fee date.
You may also be interested in...
CV Therapeutics' complete response to FDA's October 2003 "approvable" letter is based on the ERICA trial in patients refractory to the maximum labeled dose of Pfizer's calcium channel blocker Norvasc.
Audits of European clinical trial sites have shown “more audit observations than the FDA was comfortable with,” CV Therapeutics says. The 90-day extension will allow for further audits of the EUROPA trial sites. CVT may add a product for its cardiovascular sales team to promote alongside Aceon and Ranexa.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.